Sign in to view your progression
Program Overview Progr...
Learning Objectives Learn...
Target Audience Targe...
References Refer...
Disclosure/Disclaimer Discl...

Activity Title: Seasonal Influenza: Global Burden, Prevention and the impact of COVID-19 on Surveillance and Transmission

Release Date: April 27, 2021

Estimated Time to Complete Activity: 70 minutes

Statement of Need:
WHO estimates that seasonal influenza may result in 290,000 – 650,000 deaths each year due to respiratory diseases alone. This estimate does not take into account deaths from other diseases such as cardiovascular disease, which can be influenza-related. Surveillance and laboratory studies of all influenza-related diseases are ongoing and are expected to reveal substantially higher estimates of disease burden. Experts provide updates on global influenza surveillance efforts and estimated burden of disease. They  discuss the importance of country-level influenza estimates to inform national and global preparedness, prevention and control efforts and they highlight remaining gaps. The clinical, social, and economic advances gained from expanded access and uptake of influenza vaccines are addressed and the lack of reliable data on the possible impact of vaccination among specific high-risk groups is highlighted.  

The full impact of COVID-19 and nonpharmaceutical interventions on seasonal influenza remains to be determined. Experts discuss questions around the impact of COVID-19 on influenza surveillance, the role of genomic sequencing for influenza surveillance as a way to better understand disease spread and improve prevention efforts and what to expect during the next influenza season. 

Faculty:

Dr. Ann R. Falsey, MD
Professor of Medicine,  University of Rochester School of Medicine
 
Professor Bruno Lina
Professor of Virology in the Université de Lyon, head of the Virology lab of the Hospices Civils de Lyon, director of the French National Reference Centre for respiratory viruses (including Influenza), director of the French National Reference Centre for Enterovirus, and head of the « VIRPATH» team in the CIRI INSERM, CNRS and Université de Lyon research centre.

Technical Requirements

This site and its activities are best viewed using the latest versions of the Chrome, Edge, Firefox and Safari browsers. For interactive content a broadband connection is required. For CME/CE activities featuring audio you need a sound card and speakers.

Our activities may require JavaScript to be enabled on your computer. If you are having difficulty viewing pop-up windows, click here for instructions on enabling JavaScript.

Contact Information

If you have questions about this CME activity, please contact The International Society for Infectious Diseases at  info@isid.org.

For technical support issues, please contact Multilearning at support@multilearning.com

Upon completion of this module, participants should be able to:

  • State the impact of seasonal influenza on deaths resulting from respiratory diseases and deaths from other diseases such as cardiovascular disease, which can be influenza-related
  • Discuss current and ongoing surveillance and laboratory studies of all influenza-related diseases which are expected to reveal substantially higher estimates of the disease burden
  • Describe updates on global influenza surveillance efforts and the estimated burden of disease.
  • Explain the importance of country-level influenza estimates to inform national and global preparedness, prevention and control efforts
  • Summarize the clinical, social, and economic advances gained from expanded access and uptake of influenza vaccines and the lack of reliable data on the possible impact of vaccination among specific high-risk groups 
  • Recognize that the full impact of COVID-19 and nonpharmaceutical interventions on seasonal influenza remains to be determined. 
  • Discuss the impact of COVID-19 on influenza surveillance
  • Describe the role of genomic sequencing for influenza surveillance as a way to better understand disease spread and improve prevention efforts 
  • Relate what to expect during the next influenza season.

 Physicians, nurses, public health officials, researchers, and other health professionals

The World Health Organization – Tools to measure Influenza Disease Burden: https://www.who.int/influenza/surveillance_monitoring/bod/en/
 
Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)33293-2/fulltext
 
Decreased Influenza Activity During the COVID-19 Pandemic — United States, Australia, Chile, and South Africa, 2020. https://www.cdc.gov/mmwr/volumes/69/wr/mm6937a6.htm
 
European Centre for Disease Prevention and Control – Seasonal Influenza. https://www.ecdc.europa.eu/en/seasonal-influenza

Disclosure Policy

In accordance with the EACCME Standards for Commercial Support, the International Society for Infectious Diseases (ISID) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. ISID  resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all our educational programs. Furthermore, ISID seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. ISID is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Activity Staff Disclosures:

The planners, reviewers, editors, staff, or other members at the International Society for Infectious Diseases who control content have no relevant financial relationships to disclose. 

ISID Knowledge Exchange and E-Learning Platform Organizing Committee members are listed here along with Committee members’ disclosure forms. 

Faculty Disclosures:

Professor Bruno Lina has no actual or potential conflict of interest in relation to this program/presentation

Dr. Ann F. Falsey's disclosures:
Grants/Research Support:  Pfizer, Janssen Pharmaceuticals, Astra Zeneca, BioFire Diagnostics
Honoraria/Consultation fees: Novavax - DSMB 

Moderator Disclosures:

Prof. Patricio Acosta and Dr. Thérèse Umuhoza have no actual or potential conflict of interest in relation to this program/presentation

Prof. Zamberi Sekawi:
Grants/Research Support: Sanofi Pasteur
Honoraria/Consultation Fees: Sanofi Pasteur, Pfizer
Company Sponsored Speakers Bureau: Sanofi Pasteur

Disclosure of Unlabeled Use

The International Society for Infectious Diseases  requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. ISID does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Disclaimer

The International Society for Infectious Diseases presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The International Society for Infectious Diseases, and the former commercial supporter assume no liability for the information herein.

Copyright Information

Copyright © 2021 by the International Society for Infectious Diseases. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

•  The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.

•  Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without the International Society for Infectious Diseases' prior written permission.

Privacy Policy

The International Society for Infectious Diseases protects the privacy of personal and other information regarding participants and educational collaborators. The International Society for Infectious Diseases will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

The International Society for Infectious Diseases maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.

Additional information regarding the International Society for Infectious Diseases Privacy Policy and ISID’s Knowledge Exchange and E-Learning Platform Privacy Policy can be viewed at https://isid.org/privacy-policy/ and https://exchange.isid.org/isid/legal/terms-and-conditions.

Seasonal Influenza: Global Burden, Prevention and the impact of COVID-19 on Surveillance and Transmission

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies